Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy

Abstract Background To evaluate the predictive value of AR-V7 expression detected by immunohistochemical (IHC) in prognosis prostate cancer patients receiving adjuvant hormonal therapy (AHT) following radical prostatectomy (RP). Methods We retrospectively collected data 110 with RP, followed AHT, from Tongji hospital. IHC analysis was performed a retrospective cohort. Results In total, were enrolled, whom 21 (19.1%) AR-V7-positive and 89 (80.9%) AR-V7-negative. No significant differences baseline characteristics found between two groups. had shorter progression-free survival (PFS) (HR: 4.26; 95% CI, 1.55 to 11.68; P = 0.003), cancer-special (CSS) 22.47; 2.912 173.4; 0.003) overall (OS) 6.61; 1.40 31.20; 0.017) compared AR-V7-negative patients. multivariate analysis, is an independent risk factor for PFS (HR, 3.76; 1.63 8.70; 0.002), CSS 9.17; 1.48 55.56; OS 4.81; 1.28 17.86; 0.020). Conclusion The presence tissue independently associated unfavorable PFS, who received AHT.